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Abstract 
Objective: To explore the relationship between tumor necrosis factor receptor‑associated factor 6 (TRAF6) and the 
clinicopathological features in HCC as well as its biological function.
Methods: Totally, 412 liver tissues were collected, including 171 hepatocellular carcinoma (HCC) and their corre‑
sponding non‑tumor tissues, 37 cirrhosis and 33 normal liver tissues. The expression of TRAF6 was assessed by immu‑
nohistochemistry. Then, analysis of the correlations between TRAF6 expression and clinicopathological parameters 
in HCC was conducted. Furtherer, in vitro experiments on HepG2 and Hep3B cells were performed to validate the 
biological function of TRAF6 on HCC cells. TRAF6 siRNA was transfected into HepG2 and Hep3B cell lines and TRAF6 
expression was evaluated with RT‑qPCR and western blot. The assays of cell viability, proliferation, apoptosis and cas‑
pase‑3/7 activity were carried out to investigate the effects of TRAF6 on HCC cells with RNA interference. Cell viability 
was assessed with Cell Titer‑Blue kit. Cell proliferation was tested with MTS kit. Cell apoptosis was checked through 
morphologic detection with fluorescence microscope, as well as caspase‑3/7 activity was measured with fluorogenic 
substrate detection.
Results: The positive expression rate of TRAF6 protein was 49.7 % in HCC, significantly higher than that of normal 
liver (12.1 %), cirrhosis (21.6 %) and adjacent non‑cancerous tissues (36.3 %, all P < 0.05). Upregulated TRAF6 was 
detected in groups with metastasis (Z = −2.058, P = 0.04) and with low micro‑vessel density (MVD) expression 
(Z = −2.813, P = 0.005). Spearman correlation analysis further showed that the expression of TRAF6 was positively 
correlated with distant metastasis (r = 0.158, P = 0.039) and negatively associated with MVD (r = −0.249, P = 0.004). 
Besides, knock‑down of TRAF6 mRNA in HCC cell lines HepG2 and Hep3B both resulted in cell viability and prolifera‑
tion inhibition, also cell apoptosis induction and caspase‑3/7 activity activation.
Conclusions: TRAF6 may contribute to metastasis and deterioration of the HCC via influencing cell growth and 
apoptosis. Thus, TRAF6 might become a predictive and therapeutic biomarker for HCC.
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Background
Hepatocellular carcinoma (HCC) is the fifth most fre-
quent malignancy in the world [1]. With a mortality rate 
of about one million per year, it ranks the third leading 
cause of cancer deaths worldwide [2]. Roughly, 80 % HCC 
patients, among all cases, live in the Asia–Pacific region 
and Sub-Saharan Africa area while the incidence has also 
increased markedly in Europe and the United States [3–
5]. It has been estimated that there would be 35,660 new 
cases with liver cancer in America in 2015 [6]. Several 
environmental factors are considered to be contributed 
to the main causes of HCC, such as long-time exposure 
to aflatoxin B1, hepatitis B and C viral infections and 
alcohol abuse [7–9]. Despite great progress has been 
made in diagnosis and therapy for HCC, there are limi-
tations in early detection, and the patients in advanced 
stage, when diagnosed, generally face a dismal prognosis 
and a high incidence of recurrence [10, 11]. At present, 
α-fetoprotein (AFP) is the common clinical diagnostic 
criteria for HCC [12], especially in Asia. However, its 
specificity and sensitivity are not satisfied [13]. Therefore, 
identifying reliable novel biomarkers for the early screen-
ing and prediction of HCC arouses our interest.
Tumor necrosis factor receptor-associated factors 
(TRAFs) are a group of cytoplasmic adapter proteins 
which link a wide range of cell surface receptors. TRAFs 
mediate intracellular signal transduction, including 
tumor necrosis factor (TNF), toll-like receptor (TLR), 
interleukin-1 receptor (IL-1R) and superfamily trans-
forming growth factor-β (TGF-β) [14, 15]. As a result, 
TRAFs lead to the activation of mitogen-activated pro-
tein and nuclear factor kappa B (NF-κB) kinases [16]. 
Additionally, TRAFs also interact with varieties of pro-
teins which regulate receptor-induced cell death and 
survival [16]. Therefore, TRAF-mediated signal cascades 
may directly cause the receptor-induced apoptosis and 
interfere with cell survival.
Among the six TRAF family members, TRAF6 is 
unique. TRAF6 is involved in a variety of physiologi-
cal processes, including congenital immunity, adap-
tive immunity, and inflammation [17–19]. TRAF6, 
functioning as a signal transducer, is a key activator of 
NF-κB pathway which activates inhibitor of IκB kinase 
in response to proinflammatory cytokines [20, 21]. In 
recent years TRAF6 has been found to play some roles 
in carcinogenesis in some cancers, such as lung cancer 
[22], glioblastoma [23], and squamous cell carcinoma 
[24]. However, none of the studies have cast light upon 
the expression and function of TRAF6 and its association 
with HCC. Thus, in order to investigate the relationship 
between TRAF6 and clinicopathological parameters of 
HCC, whether TRAF6 plays a role in the proliferation 
and apoptosis process of HCC or not, we carried out the 
current study, quantifying the TRAF6 differential expres-
sion in liver tissues with continuous pathological states, 
which could lead to potential development of HCC using 
immunohistochemistry (IHC) technique, and testing the 
effects of silencing TRAF6 in HCC HepG2 and Hep3B 
cell lines with in vitro experiments.
Methods
Study design and experimental grouping design
The study was concentrated on the following three parts. 
Firstly, the expression of TRAF6 was compared between 
group of HCC and non-HCC liver tissues. Groups of non-
HCC liver tissues included group of para-tumor liver tissue, 
group of cirrhosis liver tissue and group of normal liver tis-
sue. Secondly, the relationship between TRAF6 and clinico-
pathological data of HCC patients was analyzed. Subgroup 
classification was based on different status of each clinico-
pathological data, including age, gender, tumor differen-
tiation, tumor size, number of tumor nodes, metastasis, 
clinical TNM stages, status of portal vein tumor embolus, 
vaso-invasion condition, capsular infiltration, hepatitis C 
virus (HCV) and hepatitis B virus (HBV) infection status, 
AFP expression, cirrhosis, as well as nm23, p53, p21, vas-
cular endothelial growth factor (VEGF), Ki-67 expression 
and micro-vessel density (MVD) level as stained by CD34. 
Thirdly, in vitro experiments on HCC cell lines, including 
HepG2 and Hep3B, were performed to validate the biologi-
cal function of TRAF6 on HCC cells. The cell viability, cell 
proliferation, cell apoptosis and Caspase-3/7 activity were 
compared between the group of negative controls and the 
group transfected with TRAF6 siRNA.
Tissue samples
HCC tissues (n  =  171) and their corresponding para-
cancer tissues, 37 cirrhosis liver tissues and 33 normal 
liver tissues were collected from patients or autopsies 
admitted to the First Affiliated Hospital, Guangxi Medi-
cal University from March 2010 to December 2012. All 
these HCC tissues were taken from patients with primary 
HCC, who had not received any other treatment before 
surgery. The clinicopathological data of 171 HCC patients 
were listed above. All the formalin-fixed, paraffin embed-
ded (FFPE) liver tissues were evaluated retrospectively, 
and their diagnoses were confirmed by two experienced 
pathologists independently. Besides, enzyme-linked 
immunosorbent assay (ELISA) was used to measure AFP 
level in sera and IHC was applied to detect nm23, p53, 
p21, VEGF, Ki-67 and MVD. All the features above were 
recorded. The study was approved by the Ethical Com-
mittee of the First Affiliated Hospital of Guangxi Medi-
cal University. Informed consent was signed by all of the 
patients who participated in the study. Related research 
procedure complied with the Helsinki Declaration.
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Immunohistochemistry
Immunohistochemical technique was used to detect the 
expression of TRAF6. The TRAF6 antibody obtained 
from Santa Cruz Biotechnology, lnc. (D-10, sc-8409, 
1:300 dilution, Heidelberg, Germany) was applied to 
antigen–antibody interaction. TRAF6 Antibody (D-10) 
is a mouse monoclonal IgG1 provided at 200 µg/ml and 
it is raised against amino acids 1–274 mapping at the 
N-terminus of TRAF6 of human origin. All the experi-
mental operations were completed strictly according fol-
lowing instructions. Two pathologists reviewed the H&E 
sections and scored the staining independently, without 
knowing the status of the samples. The scoring standards 
were defined as follows [25]: (1) the staining intensity 
was marked from 0 to 3 points, 0 for no staining, 1 for 
weak, 2 for moderate and 3 for strong. (2) The positive 
expression rate ranged from 0 to 4 points, 0 stands for no 
staining, 1 for <25 %; 2 for 26 to 50 %, 3 for 51 to 75 %, 
and 4 for >75 %. (3) The points of staining intensity plus 
the points of positive expression rate resulted in the final 
expression score.
Culture and transfection of the cell lines
Human HCC cell lines HepG2 and Hep3B were pur-
chased from Shanghai Institute of Cell Biology of Chi-
nese Academy of Sciences. Cells were cultured in the 
RPMI1640 medium with 10 % fetal bovine serum at 37 ℃ 
in a 5  % CO2 incubator. HepG2 and Hep3B cells were 
inoculated in 96 or 24-well plates and cultured for 24 h. 
Cell confluence was controlled at 50 to 60 % when cells 
were transfected with TRAF6 siRNA with Lipofectamine 
2000 reagent (Invitrogen). After the transfection, we 
chose 0, 5 and 10 days as time points to detect the effects 
of TRAF6 siRNA on the malignant phenotypes of HCC 
cells.
Real time RT‑qPCR and Western blot
TRAF6 expression of the HepG2 and Hep3B cell lines 
transfected with TRAF6 siRNA was measured with real 
time RT-qPCR and western blot.
The TRAF6 mRNA level was determined after 5 
and 10  days post-transfection by RT-qPCR. Briefly, 
total cellular RNA isolation was performed with 
RNeasy Mini kit (Qiagen, Hilden, Germany). RNA 
concentrations were evaluated with a ND-2000 Nan-
oDrop (Thermo Fisher Scientific, Wilmington, Dela-
ware USA). Two hundred nanogram of cellular RNA 
was converted to cDNA with a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) in a 
total volume of 10  μl. The primers for TRAF6 were: 
forward 5′- AGGGACCCAGCTTTCTTTGT-3′ and 
reverse 5′- GCCAAGTGATTCCTCTGCAT-3′. The 
primers for GAPDH were: forward 5′-TGAAGGTC 
GGAGTCAACGGATTTGGT-3′ and reverse 5′-CATGT 
GGGCCAT GAGGTCCACCAC-3′. RT-qPCR analysis 
was carried out on a LightCycler 1.5 using the Faststart 
DNA master SYBR green mastermix. Quantitative values 
were obtained from the PCR quantification cycle num-
ber (Cq) at which point the increase in signal for the PCR 
product was exponential. The target mRNA abundance 
in each sample was normalized to its GAPDH mRNA 
level as ΔCq = CqTRAF6−CqGAPDH. The value ΔΔCq was 
defined as the difference with a mock transfected control. 
Experiments were performed in triplicate. The knock-
down ratio of TRAF6 mRNA expression was calculated 
with the formula: (1−1/2ΔΔCq) × 100 %.
For western blot, totally, 25 μg proteins obtained from 
the cell lines were added in 8  % SDS-PAGE separation 
gel. Then the mixture was transferred to nitrocellulose 
membranes and probed with primary antibodies against 
TRAF6 (D-10, sc-8409, dilution: 1:500, Santa Cruz Bio-
technology). After incubating with horseradish peroxi-
dase (HRP)-conjugated secondary antibodies (D-3004), 
enhanced chemiluminescence detection was performed 
to identify the expression levels of TRAF6 protein.
Cell viability assay
The assay was conducted with Cell Titer-Blue kit (G8080, 
Promega, USA). The detection time points were set on 
0th, 5th and 10th day after transfection. The cell viabil-
ity was determined with FL600 fluorescent detector (Bio-
Tek, USA) at 560 nm or 590 nm.
Cell proliferation assay
Cell proliferation was measured with MTS kit accord-
ing to manufacturer’s instructions on 0th, 5th and 10th 
day post transfection. The medium was cleared out and 
washed with phosphate-buffered saline twice. Fetal 
bovine serum of 10 % and MTS reagents were added to 
subset of wells. After the cells were incubated for 2  h, 
absorbance at 490  nm was measured with a microplate 
reader (Thermo).
Apoptosis assay
Cells were washed with cold phosphate-buffered saline 
and stained with 1 mg/ml Hoechst 33342 and 1 mg/ml PI 
for 15 min, fluorescence microscope (ZEISS Axiovert 25) 
was then used to observe the cellular morphology and 
staining changes. Ten different photos were taken under 
200 times visual sight. The judging criterion was as fol-
lows: (1) Positive Hoechst 33342 staining and negative PI 
staining was found in living cells with complete shape. (2) 
Early apoptotic cells were stained with positive Hoechst 
and negative PI, containing blue apoptotic bodies, while 
apoptotic cells in the late phase were stained with nega-
tive Hoechst and positive PI, containing red apoptotic 
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bodies. (3) Necrotic cells were those cells with negative 
PI staining but with none apoptotic bodies.
Caspase‑3/7 activity assay
After the cell viability assay was completed, we carried 
out the experiments on the same 96-well were to detect 
caspase-3/7 activity by adding caspase-3/7 reagents. 
Then the cells were incubated for an hour. Fluorescence 
intensity was measured at 499 nm or 512 nm with FL600 
fluorescent detector (Bio-Tek, USA).
Statistical analysis
SPSS21.0 was employed for statistical analysis. Kruskal–
Wallis H tests were applied to analyze the status of 
TRAF6 protein expression among normal, cirrhosis, 
para-cancer and HCC tissues as well as their pathologi-
cal grades. Mann–Whitney U tests were performed to 
identify the expression of TRAF6 in different subgroups 
with other clinicopathological features, including age, 
gender, tumor size, tumor nodes, metastasis, clinical 
TNM staging and so on. Correlation between the TRAF6 
expression and clinicopathological features was detected 
with Spearman analysis. Furthermore, we performed 
receiver operating characteristic (ROC) curve to analyze 
the diagnostic ability of TRAF6 expression. Compari-
sons among groups of blank control, siRNA control and 
TRAF6 siRNA were performed with One-Way ANOVA 
or Kruskal–Wallis H tests. A P value less than 0.05 was 
considered statistically significant.
Results
TRAF6 expression in HCC tissues and non‑cancer tissues
The positive expression rate of TRAF6 protein was 49.7 % 
(85/171) in HCC tissues, significantly higher than para-
carcinoma liver tissues (36.3 %, P = 0.012), cirrhosis tis-
sues (21.6 %, P = 0.002), and normal liver tissues (12.1 %, 
P  <  0.001, Table  1, Fig.  1). Difference was also found 
between para-carcinoma liver tissues and normal liver 
tissues (Z = −2.707, P = 0.007). However, no statistical 
significance was observed when comparing cirrhotic liver 
tissues with para-carcinoma tissues or with normal tis-
sues (P > 0.05).
Relationships between TRAF6 expression 
and clinicopathological parameters in HCC
Correlations between the expression of TRAF6 pro-
tein and clinicopathological features were analyzed. 
The TRAF6 level was higher in patients with metastasis 
than those without. Increasing positive expression rate 
of TRAF6 was discovered in the cases with low level of 
MVD (Table  2). The area under ROC curve (AUC) of 
TRAF6 expression to predict metastasis and MVD were 
0.579 (95 % CI 0.493–0.665) and 0.624 (95 % CI 0.527–
0.721, Fig.  2), respectively. Moreover, Spearman cor-
relation results showed that the expression of TRAF6 
was significantly associated with distant metastasis 
(r = 0.158, P = 0.039) and MVD (r = −0.249, P = 0.004). 
However, no significant correlation was found between 
the expression of TRAF6 and other parameters.
Inhibitory effect of TRAF6 on cell growth
The knock-down efficiency was satisfactory (70–90 %) as 
assessed by real time RT-qPCR (data not shown) and west-
ern blot on the 5th and 10th day post transfection (Fig. 3). 
To evaluate the effects of TRAF6 on cell viability in the 
HepG2 and Hep3B cell lines, we conducted Cell Titer-Blue 
kit and Hoechst/PI analysis. The cell Titer-Blue kit results 
showed that cell viability was suppressed on the 5th day 
and 10th day after TRAF6 siRNA transfection on both 
two cell lines. Moreover, as shown in Fig.  4, cell viability 
was significantly inhibited on the 5th day and 10th day for 
both cell lines (HepG2: P = 0.004 on the 5th day, P < 0.001 
on the 10th day; Hep3B: P  <  0.001 on 5th, 10th day). 
The results with Hoechst/PI method were in line with 
results with Cell Titer-Blue kit, however, a bit different. 
In the HepG2 cells, the statistical difference among blank, 
Table 1 Expression of TRAF6 Protein in different tissues
Tissue Patients(N) TRAF6 negative N (%) TRAF6 positive N (%) Z P
HCC VS
HCC tissue 171 86 (50.3) 85 (49.7) _ _
Para‑carcinoma tissue 171 109 (63.7) 62 (36.3) −2.509 0.012
Cirrhotic tissue 37 29 (78.4) 8 (21.6) −3.108 0.002
Normal liver tissue 33 29 (87.9) 4 (12.1) −3.976 0.001
Para VS
Cirrhotic tissue 37 29 (78.4) 8 (21.6) −1.704 0.088
Normal liver tissue 33 29 (87.9) 4 (12.1) −2.707 0.007
Cirrhosis VS
Normal liver tissue 33 29 (87.9) 4 (12.1) −1.045 0.296
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negative siRNA control and TRAF6 siRNA groups was 
only found on the 10th day after transfection (P < 0.001) 
(Fig. 4). In addition, the cell viability after TRAF6 siRNA 
transfection was obviously reduced on the 5th, 10th day in 
Hep3B cells (both P < 0.001). The effects of TRAF6 on cell 
proliferation were further analyzed by MTS assay tech-
nique, a common technology to confirm cell proliferation 
status. The MTS assay data revealed that cell proliferation 
was inactive after being treated with TRAF6 siRNA on the 
5th day and 10th day in HepG2 cells as well as Hep3B cells 
(Fig.  4), with P value less than 0.001. Thus, these results 
suggested that the suppression of TRAF6 reduced the cell 
growth of HCC HepG2 and Hep3B cells.
TRAF6 siRNA transfection enhanced the cell apoptosis 
and caspase activity
The Hoechst/PI assay was used to investigate the effects 
of TRAF6 on the cell apoptosis. Cell apoptosis was 
enhanced after being transfected with TRAF6 on the 5th 
day (P = 0.021) and 10th day (P = 0.039) in the HepG2 
cell lines, compared with groups of negative siRNA, 
and blank control (Figs.  5, 6). Similar significant differ-
ence of cell apoptosis was seen among groups of TRAF6 
siRNA, negative siRNA, and blank control on the 5th day 
(P = 0.019) and 10th day (P = 0.045) in the Hep3B cell 
lines (Figs. 5, 6). Considering the caspase-3/7 activity as 
reflection of cellular apoptosis, we quantitated the cas-
pase-3/7 activity in both HepG2 and Hep3B cell lines. As 
shown in the Fig. 5, the activity of caspase-3/7 was signif-
icantly higher in HepG2 cells treated with TRAF6 siRNA 
than groups of blank control and negative siRNA control 
on the 5th day (P = 0.035) and 10th day (P = 0.022). Con-
sistent statistical significance was found in the Hep3B 
cell lines (Fig. 5). The results indicated that TRAF6 could 
inhibit cell apoptosis and caspase-3/7 activity in HCC 
HepG2 and Hep3B cells.
Discussion
HCC is one of the most common, aggressive and lethal 
cancers in the world [26]. Owing to its burden to human 
health, early and effective diagnosis is of vital importance. 
As the genomic researches develop, increasing num-
bers of novel molecular biomarkers have been regarded 
as specific diagnosis predictor and targeted therapeutic 
agents for HCC [27–30]. However, most of those molec-
ular biomarkers for diagnosis and treatment have not 
been clearly clarified. Additionally, the carcinogenesis of 
Fig. 1 Expression pattern of TRAF6 in different liver tissues. Immuno‑
histochemistry was performed to detect the TRAF6 expression in nor‑
mal liver tissues (a), cirrhosis (b), para‑tumor liver tissues (c, left side), 
and hepatocellular carcinoma tissues (c, right side, d and e). ×400
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Table 2 Relationship between the expression of TRAF6 and clinicopathological features in HCC
Clinicopathological 
parameters
n TRAF6 negative n (%) TRAF6 positive n (%) Z P Correlation
r p
Age
<50 67 37 (55.2) 30 (44.8) −1.032 0.302
≥50 104 49 (47.1) 55 (52.9)
Gender
Male 153 76 (49.7) 77 (50.3) −0.471 0.638 −0.036 0.639
Female 18 10 (55.6) 8 (44.4)
Differentiation
High 20 14 (70.0) 6 (30.0) 3.685* 0.158 0.116 0.130
Moderate 98 48 (49.0) 50 (51.0)
Low 53 24 (45.3) 29 (54.7)
Size
<5 cm 58 34 (58.6) 24 (41.4) −1.556 0.120 0.119 0.120
≥5 cm 113 52 (46.0) 61 (54.0)
Tumor nodes
Single 68 29 (42.6) 39 (57.4) −0.370 0.711 −0.033 0.713
Multiple 61 28 (45.9) 33 (54.1)
Metastasis
– 90 52 (57.8) 38 (42.2) −2.058 0.040 0.158 0.039
+ 81 34 (42.0) 47 (58.0)
Clinical TNM stage
I ~ II 48 29 (60.4) 19 (39.6) −1.649 0.099 0.126 0.099
III ~ IV 123 57 (46.3) 66 (53.7)
Portal vein tumor embolus
– 84 37 (44.0) 47 (56.0) −0.043 0.966 −0.004 0.966
+ 45 20 (44.4) 25 (55.6)
Vaso-invasion
– 77 34 (44.2) 43 (55.8) −0.008 0.993 0.000 0.993
+ 52 23 (44.2) 29 (55.8)
Tumor capsular infiltration
Yes 61 27 (44.3) 34 (55.7) −0.016 0.987 0.001 0.987
No 68 30 (44.1) 38 (55.9)
HCV
– 87 40 (46.0) 47 (54.0) −0.587 0.557 0.052 0.559
+ 42 17 (40.5) 25 (59.5)
HBV
– 24 9 (37.5) 15 (62.5) −0.728 0.466 −0.064 0.469
+ 105 48 (45.7) 57 (54.3)
AFP
– 56 24 (42.9) 32 (57.1) −0.748 0.455 0.072 0.457
+ 54 27 (50.0) 27 (50.0)
Cirrhosis
– 74 33 (44.6) 41 (55.4) −1.298 0.194 0.100 0.195
+ 97 53 (54.6) 44 (45.4)
nm23
– 25 7 (28.0) 18 (72.0) −1.808 0.071 −0.160 0.070
+ 104 50 (48.1) 54 (51.9)
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HCC is a multistep process and the mechanism of tum-
origenesis and deterioration of HCC has not been fully 
confirmed. Therefore, we devoted great efforts to look for 
novel biomarkers of HCC and cast light on the potential 
role that TRAF6 might play in the genesis and progres-
sion of HCC.
Several studies have paid close attention on the 
role of TRAF6. For instance, Liu et  al. proposed that 
TRAF6 might be considered as a potential target for 
the treatment of Multiple myeloma (MM) as the recep-
tor activator of nuclear factor-kappaB/receptor activator 
of nuclear factor-kappa B ligand/tumor necrosis fac-
tor receptor-associated factor (RANK/RANKL-TRAF6) 
signal pathway mediated osteolytic bone lesions [22]. 
Our previous study got the conclusion that TRAF6 may 
become a target for diagnosis and gene treatment for 
lung cancer patients as the TRAF6 had a higher level of 




n TRAF6 negative n (%) TRAF6 positive n (%) Z P Correlation
r p
P53
– 54 25 (46.3) 29 (53.7) −0.408 0.683 0.036 0.685
+ 75 32 (42.7) 43 (57.3)
P21
– 84 36 (42.9) 48 (57.1) −0.414 0.679 −0.037 0.681
+ 45 21 (46.7) 24 (53.3)
VEGF
– 33 13 (39.4) 20 (60.6) −0.640 0.522 −0.057 0.524
+ 96 44 (45.8) 52 (54.2)
Ki-67 LI
Low 62 26 (41.9) 36 (58.1) −0.803 0.422 −0.073 0.424
High 61 30 (49.2) 31 (50.8)
MVD
Low 61 19 (31.1) 42 (68.9) −2.813 0.005 −0.249 0.004
High 68 38 (55.9) 30 (44.1)
* Kruskal–Wallis H test; − Negative; + Positive; LI label index; MVD micro-vessel density
Fig. 2 Receiver operating characteristic (ROC) curve of TRAF6 expression in hepatocellular carcinoma (HCC) tissues. The area under ROC curve 
(AUC) of TRAF6 was calculated to to predict the metastatic status and micro‑vessel density (MVD) in HCC tissues
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tissues [31]. Chiu et  al. suggested that TRAF6 inhibi-
tion might represent a new therapeutic strategy for 
pancreatic cancer as the down-regulation of TRAF6 
led to a remarkable increase in autophagy and apopto-
sis [32]. However, only Xu Z et al. focused on the rela-
tionship between TRAF6 and HCC. They indicated that 
Cezanne2 interacted with TRAF6 and cleaved the poly-
ubiquitin from TRAF6 substrates whose suppression 
might have a key role in the HCC malignancy transfor-
mation [33]. However, the study was lack of in vivo and 
in vitro verification.
In the current study, different from previous experi-
ment methods comparing only normal liver tissues and 
HCC tissues, we examined TRAF6 expression in contin-
uous liver tissues, including normal liver, cirrhosis, para-
cancer liver and HCC tissues, which gave us a chance to 
observe a relatively continuous expressional change of 
TRAF6 in the genesis of HCC. Positive TRAF6 expres-
sion rates were 12.1, 21.6, 36.3, 49.7 % in the normal, cir-
rhosis, para-cancer and HCC tissues, respectively. The 
results showed an increasing expression trend in the 
process of carcinogenesis. Moreover, we performed ROC 
curve to analyze its diagnostic ability. That we found the 
AUC of TRAF6 was 0. 595 in HCC, lower than that in 
lung cancer which was 0.663, indicated the diagnosis 
value of TRAF6 was moderate for HCC or lung cancer 
[31]. However, coexistent significant statistical differ-
ences were not observed in the dynamic development 
of liver cancer. Namely, significant differences were only 
found apart between normal and HCC tissues (P < 0.001), 
cirrhosis and HCC tissues (P =  0.002), para-cancer and 
HCC tissues (P  =  0.012), normal and para-cancer tis-
sues (P = 0.007). This may be due to the limitation of case 
number. Further larger cirrhosis and normal samples 
should be enrolled to investigate the differential expres-
sion in the dynamic development of HCC.
In order to explain the role of TRAF6 in the HCC 
angiogenesis, we quantified the expression of VEGF 
and MVD in this study. No correlation was found 
between TRAF6 and VEGF, while TRAF6 was associ-
ated with MVD closely (r = −0.249, P =  0.004). This 
indicated that TRAF6 might act as a repressor in the 
angiogenesis of HCC. However, the AUC of MVD was 
0.624, lacking high accuracy in predicting the status 
of micro-vessels. Besides, TRAF6 was connected with 
metastasis (r = 0.158, P = 0.039). Although VEGF and 
MVD were able to predict vascular metastasis and 
invasion of HCC [34], the role of TRAF6 in contribut-
ing to metastasis did not lie in the aspect of angiogen-
esis, as indicated above.
To confirm the biological function of TRAF6 in HCC 
cells, we focused on the application of siRNA interference 
technology with in vitro experiments, using HepG2 and 
Hep3B cell lines. We found that cell growth was inhibited 
in both two cell lines after TRAF6 was knocked-down 
with siRNA. Since good cell viability is important for cel-
lular material transporting, high expression of TRAF6 
might promote cancer growth by keeping cancer cells 
alive. As is known, cell proliferation and apoptosis play 
important roles in cancers, we also explored the effects of 
TRAF6 on cell proliferation and apoptosis by its knock-
down, and results showed that the ability of cell prolifera-
tion was reduced while the action of cell apoptosis and 
caspase activity was enhanced after TRAF6 was silenced. 
Peng et  al. reported that knock-down of TRAF6 could 
suppress cell proliferation and promote cell apoptosis in 
the glioma cell [35], and Sun and his colleagues found 
that the TRAF6 level was increased in the colon cancer 
Fig. 3 Knock‑down effeciency of TRAF6 siRNA in hepatocellular carcinoma HepG2 and Hep3B cells. HepG2 and Hep3B cells were transfected with 
TRAF6 siRNA and corresponding controls for 10 days. The protein level of TRAF6 was assessed by Western blot (1: Blank control, 2: Negative siRNA 
control, 3: TRAF6 siRNA). *P < 0.01
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Fig. 4 Effect of TRAF6 siRNA on the cell growth of HCC cells. HepG2 and Hep3B cells were transfected with TRAF6 siRNA and corresponding con‑
trols for 5 and 10 days. Cell viability was assessed by Cell Titer‑Blue kit (a HepG2, b Hep3B); Proliferation was evaluated with MTS assay (c HepG2, d 
Hep3B); Cell viability was also verified by Hoechst/PI double staining (e HepG2, f Hep3B). *P < 0.01, **P < 0.001
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and its knockdown inhibited cell proliferation but did not 
improve the survival time [36]. In general, TRAF6 may 
participate in the cell growth and apoptosis in HCC as 
well as other cancers being reported.
As for the role that TRAF6 played in cancer invasion 
and metastasis, a study on esophageal squamous cell car-
cinoma revealed that TRAF6 promoted migration and 
metastasis by regulating the RAS pathway [37]. In the 
analysis of correlations between TRAF6 expression and 
clinicopathological features, we found that high expres-
sion of TRAF6 was associated with metastasis. Although 
there was no in  vitro experiment on the metastasis in 
this study, based on existing literatures, HCC may be 
similar with esophageal squamous cell carcinoma where 
TRAF6 influences cell migration and metastasis, which 
we will perform experiments to verify.
In summary, our study revealed that the level of TRAF6 
was higher in the HCC tissues compared to normal, cir-
rhosis and para-cancer liver tissues. Meanwhile, TRAF6 
expression was related to metastasis and MVD. Most 
importantly, experiments in  vitro showed that TRAF6 
could increase the cell viability, promote cell prolifera-
tion, and inhibit cell apoptosis and caspase-3/7 activity. 
All these results elucidated that overexpression of TRAF6 
might promote HCC progression. TRAF6 may be a key 
biomarker in the HCC carcinogenesis and development. 
Fig. 5 Effect of TRAF6 siRNA on the cell apoptosis of HCC cells. HepG2 and Hep3B cells were transfected with TRAF6 siRNA and corresponding 
controls for 5 and 10 days. Cell caspase‑3/7 activity was assessed by Hoechst/PI double staining (a HepG2,b Hep3B); Apoptosis was detected by 
Hoechst/PI double staining (c HepG2, d Hep3B). *P < 0.01, **P < 0.001
Page 11 of 12Li et al. Cancer Cell Int  (2016) 16:76 
It would be beneficial to pay more attention on exploring 
the regulation mechanisms of TRAF6 in the HCC dete-
rioration in the future.
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